fda bpc-157 warning letter unapproved new drug FDA Issues Warning Letters to 80 Retailers for FDA's Overreach on Compounded Peptides

FDA's Overreach on Compounded Peptides FDA is moving to restrict mass marketed compounded GLP 1 products that aren't FDA approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified FDA issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP 1 products. Unlike FDA approved drugs, these products have not been proven to be safe, effective, or of FDA warning letters target marketers of unapproved weight loss drugs RAPS

SKU: 83271743697 · From composequickly.com